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128 Poster Session-IIStandard primary therapy for acute graft-vs.-host disease
(GVHD) is systemic corticosteroids, but failure of systemic steroids
to control acute GVHD is common and can result in very high non-
relapse mortality. Overall, fewer than 30% of patients with systemic
steroid resistant GVHD have complete or partial responses to avail-
able therapy, and 1 year survival remains 15% or less. There has been
no generally accepted therapy for systemic steroid-refractory acute
GVHD. Although little data on localized therapy for GVHD is pub-
lished, intra-arterial injection of high-dose corticosteroids appears to
be a viable option and sporadic publications have demonstrated sev-
eral positive outcomes in patients receiving intra-arterial steroids.
We report on 17 patients with systemic steroid resistant GVHD
who have been treated with intra-arterial injections of high-dose cor-
ticosteroids at our institution in the past 2 years. A total of 23 treat-
ments were performed with only three patients receiving more than
one treatment. Sixteen of the patients received treatment for GI
GVHD, of which three had concomitant hepatic involvement.
One received treatment for hepatic GVHD only. The patient with
isolated hepatic GVHD received treatments into the hepatic arteries
and all patients with GI GVHD received treatments into the supe-
rior and inferior mesenteric arteries. Six of the patients (35%) dem-
onstrated no response, and of those 3 died of GVHD and 3 died of
other complications. Five patients (29%) showed partial response.
Of these, 4 were discharged on TPN and oral meds 14 to 43 days af-
ter the intra-arterial treatment, the fifth patient became septic prior
to discharge and expired. The remaining six patients (35%) showed
complete response and were discharged on PO diet and oral meds 1
to 22 days after the intra-arterial treatment. No immediate treatment
or procedure related complications were noted. These preliminary
results reinforce that direct intra-arterial injection of methylprednis-
olone appears to be effective and safe in patients that have proven to
be resistant to systemic steroids. In two patients, one with a complete
and the other with a partial response, there was recurrence of
GVHD. These patients raise the question of whether more than
one initial treatment may be helpful in preventing recurrence.
Larger, prospective studies need to be conducted to further evaluate
this promising approach to systemic steroid refractory GVHD.
Patient Characteristics, Response, and Current Status
Location Duration Number CurrentAge/
Sex Diagnosisof
DiseasePrior
Treatmentto
Responseof
Treatments ResponseStatus (days
post IAS)63/F NHL GI IVS, INF 14 days 1 PR no GVHD (713)48/M NHL GI IVS, ATG,
INF x2, MSC21 days 1 PR cGVHD (564)58/M NHL GI IVS 12 days 1 PR D, ARDS, no
GVHD (42)41/F MM GI IVS, ATG 43 days 1 PR D, ARDS, no
GVHD (53)50/F AA GI IVS, ATG 12 days 1 CR cGVHD of
Lungs, no GI
GVHD (562)70/M NHL Hepatic IVS, ATG 22 days 1 CR no GVHD (735)60/M NHL GI IVS, INF 1 day 1 CR no GVHD (568)50/F NHL GI IVS 19 days p 1st,
7 days p 2nd2 CR no GVHD (700)71/M NHL GI IVS, INF x4,
ATG5 NR D, GVHD (15)55/M NHL GI IVS 7 days 1 CR D - perforation
secondary to
CMV colitis
(404)39/F NHL GI IVS 1 NR D, GVHD, CMV
colitis (56)70/F NHL GI IVS 1 NR D, GVHD,
sepsis (50)38/M NHL GI IVS 1 NR D, GVHD (15)60/F NHL GI IVS, INF 24 days 1 CR D, recurrent
GVHD (498)59/M NHL GI IVS, INF 2 NR D, GVHD (11)61/F MDS/
NHLGI IVS 14 days 1 PR D, sepsis, no
GVHD (34)(Continued ). (Continued )Age/
Sex DiagnosisLocation
of
DiseasePrior
TreatmentDuration
to
ResponseNumber
of
Treatments ResponseCurrent
Status (days
post IAS)50/M MDS/
NHLGI IVS, ATG 1 NR D, GVHD,
sepsis (32)IAS indicates intra-arterial steroids; NHL, non hodgkin’s lymphoma; MM,
multiple myeloma; AA, aplastic anemia; MDS, myelodysplastic syn-
drome; GI, gastrointestinal; IVS, intra-venous steroids; ATG, anti-thymo-
cyte globulin; INF, infliximab; MSC, mesenchymal stem cells; PR, partial
response; CR, complete response; NR, no response; D, dead; GVHD,
graft-vs-host disease; cGVHD, chronic GVHD; ARDS, acute respiratory
distress syndrome; CMV, cytomegalovirus.357
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Although in recent years techniques of allogeneic hematopoietic
stem cell transplantation have improved considerably to allow the
use of this procedure even for elderly and less fit patients, severe
graft-versus-host disease (GvHD) remains themain obstacle to apply
this therapeutic modality. Still, no standard therapy has been identi-
fied once a patient has developed severe acute GvHD and is refrac-
tory to high-dose steroids. The pre-emptive use of CD52 antibody
alemtuzumab as part of the conditioning regimen may lead unneces-
sarily to relapse and increased infection rates. Commercially avail-
able alemtuzumab was used in 16 patients now evaluable, age
range 13 to 68 years, with GvHD grade III and IV refractory to at
least 7 days of high-dose steroids. Patients had undergone stem
cell transplantation from family donors (n5 7) or matched unrelated
donors (n 5 9). Four had 1 or 2 antigen mismatch. All patients had
severe gut and/or liver involvement. Initially, in three patients in
rather critical situations start doses of alemtuzumab in the range of
70mg to 80mg (total) were applied in fractions over several days
and repeated after 3 to 4 weeks. Impressive responses, such as biliru-
bin levels of 48mg/dl returning to normal within several weeks, were
encouraging, but virus reactivation and bacterial infections were
seen. This finding and considering the limited quantities of lym-
phoid tissue present early after transplantation requiring less anti-
body, the starting dose was reduced to 20 to 33 mg in the second,
and 5–10mg in the third cohort, repeated every 2 to 3 weeks. CR,
or near CR, were obtained in 11 of 13 patients of these two dosage
groups. The longest follow-up is 138 months. Chronic GvHD
was frequently observed. Pronounced lymphocyte depletion seems
inevitable for efficacy, but infectious complications were limited.
Thus, despite the need for close observation for infectious complica-
tions, alemtuzumab given sequentially in moderate doses has a sub-
stantial activity in severe steroid-refractory acute GvHD.358
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Background:Extracorporeal photopheresis (ECP) is used to treat
cGVHD, but its mechanism has not been fully defined. One model
for the mechanism of ECP in cGVHD is dendritic cell (DC) deple-
tion andT-cell modification.We tested this hypothesis by determin-
ing the numbers of circulating DCs and T-cells prior to ECP and
